Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 3/20 | 0.54 |
| ▸ | CMA1 | P23946 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | PAM | P19021 | 1/20 | 0.48 |
| ▸ | CTRC | Q99895 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.47 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14363442 | 0.89 | CTSG (0.62) | CTSGCMA1CTSSCTSKGNPAT | |
| SCHEMBL14865867 | 0.89 | CTSG (0.62) | CTSGCMA1CTSSCTSKGNPAT | |
| SCHEMBL22249863 | 0.87 | CTRB1 (0.53) | CTSGCMA1ALDH1A1THRBCYP2C9 | |
| SCHEMBL29498118 | 0.86 | REN (0.56) | CTSSCTSKRENGNPATPAM | |
| SCHEMBL13022186 | 0.86 | MME (0.61) | CTSSCTSKGNPATMMEACE | |
| SCHEMBL4371865 | 0.86 | MME (0.61) | CTSSCTSKGNPATMMEACE | |
| SCHEMBL4371868 | 0.86 | MME (0.61) | CTSSCTSKGNPATMMEACE | |
| SCHEMBL13287429 | 0.84 | CTSG (0.52) | CTSGCMA1ALDH1A1THRBCYP2C9 | |
| SCHEMBL16488396 | 0.84 | CTSG (0.52) | CTSGCMA1ALDH1A1THRBCYP2C9 | |
| SCHEMBL13022187 | 0.82 | ALDH1A1 (0.69) | RENALDH1A1THRBCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136518-A1 | Compositions and methods to reduce mutagenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-28 | — | — | US | disclosed |
| US-7455840-B2 | Compositions and methods to reduce mutagenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136518-A1 | Compositions and methods to reduce mutagenesis | OGG1, DNMT3A, APOBEC3G | CTSG 1090/4885CMA1 1457/4885CTSS 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.